Abstract
The 2020 COVID-19 pandemic undermines the world economy, the affordability and accessibility of our health systems. It puts an increasing strain on global production, supply and value chains. The research and development of a set of COVID-19 vaccines is an unprecedented triumph of rapid innovation. The sense of urgency has prompted academic research institutions, big pharmaceuticals and dedicated biotechnology companies to develop vaccines targeting the SARS-CoV-2 coronavirus disease. Simultaneously, it unlocks new value for business, patients and society. Consequently, new business models have come to the forefront.
Highlights
The 2020 COVID-19 pandemic undermines the world economy, the affordability and accessibility of our health systems
Pharma and biotech companies within many cross-sector collaborations have taken the race to the limit to develop a coronavirus vaccine, simultaneously waking the general public up to an important warning sign: the time of going from concept to marketable product
3.2 The Public Private Partnership Business Model Government funding and financing of translational research performed at universities and research powerhouses have become increasingly important for the development of new vaccines
Summary
Already in 1995, Laurie Garrett made a case for “newly emerging diseases in a world out of balance”, expressing concern about the appearance of new infectious diseases. The 2020 COVID-19 pandemic undermines the world economy and has had an unprecedented impact on health systems around the world It is recalibrating businesses across sectors, not in the least in healthcare and the biopharmaceutical industry. The race to find both medicines and vaccines is reshaping the way companies – large and small – collaborate and innovate in life saving projects while maintaining the drive of competition in the long run. It triggered an unprecedented and intense level of global R&D activity and collaboration by research teams in companies and universities across the world. Manufacturing companies outside of the life sciences industry (i.e. pharmaceuticals, biotechnology, medical devices,. . . ) are forming partnerships with others to transform some of their manufacturing capacity to assemble much needed critical equipment like ventilators and respiratory appliances (Chesbrough, 2020)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
